J 2019

The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings

KOLČAVA, Jan, Monika HULOVÁ, Yvonne BENEŠOVÁ, Josef BEDNAŘÍK, Pavel ŠTOURAČ et. al.

Základní údaje

Originální název

The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings

Autoři

KOLČAVA, Jan (203 Česká republika, domácí), Monika HULOVÁ (203 Česká republika, domácí), Yvonne BENEŠOVÁ (203 Česká republika, domácí), Josef BEDNAŘÍK (203 Česká republika, domácí) a Pavel ŠTOURAČ (203 Česká republika, garant, domácí)

Vydání

MULTIPLE SCLEROSIS AND RELATED DISORDERS, OXFORD, ELSEVIER SCI LTD, 2019, 2211-0348

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30210 Clinical neurology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.889

Kód RIV

RIV/00216224:14110/19:00110102

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

000464532100033

Klíčová slova anglicky

Multiple sclerosis; Progressive multifocal leukoencephalopathy; Natalizumab; JC virus; Magnetic resonance imaging

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 8. 7. 2019 09:20, Soňa Böhmová

Anotace

V originále

Background: Natalizumab-related progressive multifocal leukoencephalopathy (PML) is associated with the presence of anti-John Cunningham virus (JCV) antibodies. The aim of this investigation was to evaluate the long-term stability of anti-JCV antibody serum levels and their relation to various demographic, clinical and radiological characteristics in patients suffering from multiple sclerosis (MS). Methods: Seventy-eight relapsing-remitting MS patients treated with natalizumab and evaluated for the presence of serum anti-JCV antibodies over a time period of 1-6 years (3-11 samples) were included in the study. Anti-JCV antibody levels and their changes were correlated with various demographic, clinical and radiological findings. Results: Median follow-up time was 43.5 months, with a median of 5.3 samples available per patient. At baseline, 46 (59%) of the patients were seropositive. During follow-up, anti-JCV antibody status changed from negative to positive or vice versa in 23% of patients. Baseline anti-JCV antibody index correlated positively with age (p = 0.03). Patients: with stable positive anti-JCV antibody index had more T2 hyperintensities (20.2 vs. 13.1; p < 0.007) on cerebral magnetic resonance imaging (MRI) and were also older than the stable negative anti-JCV antibody index group of patients (45.2.vs. 40.3 years; p < 0.01). No significant increase in T2 hyperintensities after seroconversion was revealed. Average duration from beginning of natalizumab therapy to seroconversion fit = 13) was 33 months. Annual seroconversion rate of anti-JCV antibody status was 6.5%. A baseline anti-JCV antibody index of > 0.90 (tt = 33) predicted stable seropositivity (100%), while baseline anti-JCV antibody index <0.20 did not predicted stable seronegativity (59%). PML was not diagnosed in any of the patients studied during the follow-up. Conclusions: A positive baseline anti-JCV antibody index of > 0.90 predicts stable positive JCV serostatus, in contrast with a baseline anti-JCV antibody index of <0.20, which remained negative in 59% of cases. Stable positive anti-JCV index patients have more MRI T2 hyperintensities and are older compared with stable negative anti-JCV index patients.